KRAS G12D proteolysis targeting chimeras
US12404285B2 · kind B2 · utility
0Cited by
2References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 8, 2024 |
| Grant date | Sep 2, 2025 |
| Priority date | — |
| Expiry date | Feb 21, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are KRAS G12D proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS G12D PROTACs, and methods of making and using the KRAS G12D PROTACs, e.g., to promote degradation of KRAS G12D and/or treat KRAS G12D-associated cancers. In an embodiment, the KRAS G12D PROTAC has the following structural formula: [KRAS G12Di]-L′-[Degron], or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., KRAS G12Di, L′, Degron) are as described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.